Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
Figure 5
Long-period administration of CTX improves survival compared to pre- or post-immunotherapy treatment. Mice were divided into four groups ( per group) and inoculated with a lethal dose of AB1 tumor cells on day 0. Mice received low-dose CTX before (day 3 till 10) or after (day 14 till 21) immunotherapy or metronomic dosed CTX (day 3 till 10 and day 14 till 21). Groups 2, 3, and 4 were treated with DC-immunotherapy on day 12. Group 1 functioned as a tumor control group and did not receive any treatment. Administration of metronomic dosed CTX was not significantly better than CTX treatment before () or after () immunotherapy. However, the combination of CTX and immunotherapy was significantly better than no treatment (CTX before immunotherapy compared to untreated , CTX after immunotherapy compared to untreated , metronomic dosed CTX and immunotherapy compared to untreated ).
